Hallucinogen persisting perception disorder, or HPPD, is a condition where visual disturbances from a hallucinogenic drug experience continue or return long after the drug has left your body. It affects an estimated 4% to 4.5% of people with a history of hallucinogen use, though brief flashbacks are far more common, occurring in roughly 25% to 50% of people who have used LSD.
What HPPD Looks and Feels Like
HPPD is primarily a visual condition. The disturbances it produces overlap with what someone might experience during a hallucinogenic trip, but they happen while completely sober. Common symptoms include geometric patterns appearing in your visual field, flashes or intensified colors, halos around objects, trailing images behind moving objects (like a slow shutter speed on a camera), and afterimages that persist longer than normal after looking at something bright. Some people also experience changes in how large or small objects appear.
The key distinction is that people with HPPD typically know these visual disturbances aren’t real. They’re not experiencing a psychotic break or losing touch with reality. The perceptions are unwanted intrusions into otherwise normal vision, which is part of what makes the condition so distressing for people who have it.
Type 1 vs. Type 2
Researchers often describe two subtypes, though this distinction hasn’t been formally adopted into the main diagnostic manual (the DSM-5). Type 1 is the milder form: visual symptoms are infrequent, barely affect daily life, and sometimes are even described as pleasant. It tends to resolve on its own without treatment.
Type 2 is a different experience entirely. Symptoms are persistent, potentially lasting years or even decades, and they cause significant impairment in daily and occupational functioning. The prognosis is considerably worse. That said, large-scale follow-up studies on long-term outcomes are scarce, so firm predictions about any individual case are difficult to make.
Which Drugs Cause It
LSD is the substance most commonly linked to HPPD, but it’s not the only one. In a systematic review published in the Harvard Review of Psychiatry, among 36 reported cases, 64% involved LSD use, 56% involved cannabis, 31% MDMA, 14% cocaine, 8% psilocybin, and smaller percentages involved ketamine, ayahuasca, and dextromethorphan. A substantial number of people had used multiple substances, making it difficult to pin the condition on a single drug in many cases.
One of the more unsettling aspects of HPPD is that it doesn’t necessarily appear immediately after drug use. A latent period can stretch from minutes or hours to days, or in some cases, years before symptoms surface. There’s no reliable way to predict who will develop it, and some people report onset after a single use of a hallucinogen.
How It’s Diagnosed
The DSM-5 requires three things for a diagnosis. First, you must be experiencing one or more perceptual symptoms (like those listed above) that originally developed during hallucinogen intoxication, now recurring after the drug has worn off. Second, those symptoms must cause clinically significant distress or impair your social, professional, or other important functioning. Third, the symptoms can’t be better explained by another medical condition, such as a brain tumor, infection, visual epilepsy, delirium, dementia, or schizophrenia.
That third criterion matters because HPPD shares visual symptoms with another condition called visual snow syndrome (VSS), which produces similar static-like visual disturbances but without any drug history as a trigger. A detailed drug use history is the primary way clinicians distinguish between the two. HPPD patients also tend to be older on average than those diagnosed with VSS. Eye exams including visual field testing and retinal imaging can help rule out other causes.
Treatment Options
There is no single reliable treatment for HPPD, and the evidence base is limited to case reports and small studies rather than large clinical trials. Several medication classes have shown partial improvement in reported cases, including anti-seizure medications (lamotrigine in particular has appeared in multiple reports), benzodiazepines, certain antidepressants, and a blood-pressure medication called clonidine that acts on the nervous system. Three observational studies found substantial symptom reduction with clonidine, clonazepam (a benzodiazepine), and levetiracetam (an anti-seizure medication).
The picture is complicated by the fact that different triggering drugs may respond differently to treatment. One notable finding: when HPPD was specifically triggered by LSD, benzodiazepines were ineffective. Given that finding, combined with the addiction potential of benzodiazepines, researchers have urged caution with that approach, especially for people with any history of substance dependence.
The most universally agreed-upon recommendation is complete abstinence from hallucinogens and other recreational drugs, which can prevent further episodes and, in milder cases, allow symptoms to fade over time.
Living With HPPD
For many people with Type 1 HPPD, the condition is self-limiting. Symptoms decrease in frequency and intensity and may eventually stop altogether. The experience can be unsettling, but it doesn’t typically derail daily life.
Type 2 is more challenging. Symptoms can persist for years, and the anxiety and distress they produce often become a problem in their own right. Constant visual disturbances can make it difficult to concentrate at work, drive comfortably, or relax in everyday settings. Some people find that stress, fatigue, and being in dark environments make symptoms more noticeable, though formal research on specific triggers is limited.
Because HPPD is relatively rare and not widely recognized, many people who develop it struggle to get a diagnosis. Symptoms can be mistaken for anxiety, psychosis, or dismissed entirely. If you’re experiencing persistent visual disturbances after hallucinogen use, a psychiatrist or neurologist familiar with the condition is more likely to recognize it than a general practitioner. The condition is a recognized diagnosis in both major diagnostic systems (the DSM-5 and ICD-10), so clinical awareness is growing, even if slowly.